Advertisement
Canada markets close in 3 hours

  • S&P/TSX

    21,825.23
    +116.79 (+0.54%)
     

  • S&P 500

    4,986.90
    -24.22 (-0.48%)
     

  • DOW

    37,974.03
    +198.65 (+0.53%)
     

  • CAD/USD

    0.7279
    +0.0015 (+0.21%)
     

  • CRUDE OIL

    83.27
    +0.54 (+0.65%)
     

  • Bitcoin CAD

    87,911.70
    +449.03 (+0.51%)
     

  • CMC Crypto 200

    1,377.31
    +64.69 (+4.95%)
     

  • GOLD FUTURES

    2,410.40
    +12.40 (+0.52%)
     

  • RUSSELL 2000

    1,940.11
    -2.85 (-0.15%)
     

  • 10-Yr Bond

    4.6170
    -0.0300 (-0.65%)
     

  • NASDAQ

    15,385.51
    -215.99 (-1.38%)
     

  • VOLATILITY

    18.89
    +0.89 (+4.95%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6828
    +0.0007 (+0.10%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

FREQ LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Frequency Therapeutics, Inc.

Newsfile Corp.
·1 min read

New York, New York--(Newsfile Corp. - July 28, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased Frequency Therapeutics, Inc. ("Frequency Therapeutics") (NASDAQ: FREQ) between November 16, 2020 and March 22, 2021.

If you suffered a loss, contact us at the link below. There is no cost or obligation to you.
https://www.wongesq.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?prid=18067&wire=5

Allegations against FREQ include that the Company made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

ADVERTISEMENT

If you suffered a loss in Frequency Therapeutics you have until August 2, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/91520